Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients

Table 4 Operating characteristics for the combination of squamous cell carcinoma antigen immunocomplex and alfa-fetoprotein regarding two- and five-year hepatocellular carcinoma disease-free survival

Variables	Two-year incidence in validation cohort				Five-year incidence in validation cohort
	Estimation cohort		Validation cohort		Estimation cohort		Validation cohort
	Low-risk	High risk	Low-risk	High risk	Low-risk	High risk	Low-risk	High risk
Cut-off	AFP < 5 ng/mL and SCCA-IgM < 124 AU/mL	AFP > 5 ng/mL and SCCA-IgM > 124 AU/mL	AFP < 5 ng/mL and SCCA-IgM < 124 AU/mL	AFP > 5 ng/mL and SCCA-IgM > 124 AU/mL	AFP < 5 ng/mL and SCCA-IgM < 124 AU/mL	AFP > 5 ng/mL and SCCA-IgM > 124 AU/mL	AFP < 5 ng/mL and SCCA-IgM < 124 AU/mL	AFP > 5 ng/mL and SCCA-IgM > 124 AU/mL
True positive	8	4	14	7	13	5	33	12
False positive	33	8	101	21	28	7	82	16
True negative	21	46	26	106	21	42	25	91
False negative	0	4	0	7	0	8	1	22
Sensitivity	100%	50%	100%	50%	100%	38%	96%	35%
Specificity	39%	85%	20%	83%	43%	86%	23%	85%
PPV	20%	33%	12%	25%	32%	42%	29%	43%
NPV	100%	92%	100%	94%	100%	84%	96%	81%
LR+	1.64	3.38	1.26	3.02	1.75	2.69	1.27	2.36
LR-	0.00	0.59	0.00	0.60	0.00	0.72	0.13	0.76
Correctly classified	75.8%		78.8%		61.1%		68.5%

PPV: positive predictive values; NPV: negative predictive values; LR: likelihood ratio.